CK5/6, CK7; Ki67 index was 3-5%). Since discharge the patient remains free of symptoms.
GISTs originate from the interstitial cells of Cajal and are rare [2] . They typically present in adults 40-50 years old. GISTs of the GI tract are located: 60% in the stomach; 30% in the small intestine; and 10% in the esophagus, colon, and rectum [3] . Extraintestinal tumor locations are less frequent [4] . KIT or DOG 1 are expressed in the majority of GISTs and mutations in KIT or platelet-derived growth factor receptor-α (PDGFRA) polypeptide are very common [5] . Desmin and S-100 are rarely positive [5] . Existing literature shows that esophageal GISTs usually present with upper GI complaints (dysphagia, odynophagia, regurgitation, epigastric discomfort). The majority of published cases report tumors larger than 10 cm [6] .
CT is the method of choice for primary evaluation and accurate staging of a suspected GIST. Magnetic resonance imaging has comparable diagnostic value, but may be preferred for rectum and liver GIST [7] . Positron emission tomography imaging detects smaller lesions and can dissolve diagnostic ambiguities. GI endoscopy findings may include a smooth protrusion of the wall, occasionally with signs of bleeding and ulceration. Either standard or endoscopic ultrasound-guided biopsies may not harvest enough tissue. A preoperative biopsy of a suspected resectable GIST is not recommended, but it is obligatory for metastatic disease.
The preferred method of treatment is surgical resection. If tumor size is less than 5 cm, lymph node resection is not necessary. Open surgery is indicated for large tumors, leaving laparoscopic resection for smaller tumors.
Molecular-targeted therapies, such as imatinib, may result in higher overall survival rates in high-risk patients, especially in unresectable and metastatic tumors [8] . PDGFRA mutation D842V, sporadic wild-type G, BRAF-mutated GIST, and mutations with succinate dehydrogenase rarely respond to imatinib. In patients with advanced disease in whom imatinib has failed, sunitinib is the best alternative choice [9] .
